Aspirin & The Kidneys — Nephrotoxicity, Acute Kidney Injury (AKI), and Renal Risk

Table of Contents

1. Introduction: Why Kidneys Care About COX Inhibition
2. Renal Physiology of Prostaglandins
3. Acute Kidney Injury (AKI) from Aspirin and Nonsteroidal Anti-Inflammatory Drugs
4. Analgesic Nephropathy & Papillary Necrosis
5. The "Triple Whammy": Nonsteroidal Anti-Inflammatory Drug + Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker + Diuretic
6. Aspirin in Chronic Kidney Disease (CKD)
7. Low-Dose Aspirin (81 mg) — Does It Carry Less Risk?
8. Aspirin in Dialysis Patients
9. Pediatric Considerations & Reye's Syndrome
10. Practical Guidance: Avoidance, Monitoring, Hydration
11. Key Research Papers
12. Connections
13. Featured Videos

Introduction: Why Kidneys Care About COX Inhibition

Aspirin works by irreversibly acetylating cyclooxygenase enzymes (cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2)), blocking the conversion of arachidonic acid to prostaglandins and thromboxane. In platelets this produces the antithrombotic effect that underlies aspirin's cardiovascular benefit. In the kidneys, however, the same enzymes produce vasodilatory prostaglandins — chiefly prostaglandin E₂ (PGE₂) and prostacyclin (PGI₂) — that maintain renal blood flow and glomerular filtration rate (GFR) under stress.

Under normal conditions, when a person is well-hydrated and has healthy kidneys, prostaglandins play only a minor role in regulating renal hemodynamics. But under conditions of effective volume depletion — dehydration, heart failure, cirrhosis, sepsis, hemorrhage, advanced age, or pre-existing chronic kidney disease — circulating angiotensin II, norepinephrine, and vasopressin levels rise sharply and would constrict the renal vasculature. Prostaglandins counteract this by dilating the afferent arteriole and preserving glomerular perfusion. Inhibit COX with aspirin or another nonsteroidal anti-inflammatory drug (NSAID) at this moment and the protective vasodilation disappears, glomerular filtration rate drops abruptly, and ischemic acute kidney injury can follow within hours to days.

Renal Physiology of Prostaglandins

The kidney expresses both cyclooxygenase-1 (constitutive in the medulla, vasculature, and glomerulus) and cyclooxygenase-2 (constitutive in the macula densa and medullary interstitial cells, induced by salt depletion and volume contraction). The renal prostaglandins they generate have several essential functions:

1. Afferent Arteriole Vasodilation

• PGE₂ and PGI₂ dilate the afferent arteriole, increasing blood flow into the glomerulus and supporting glomerular filtration rate
• This effect becomes critical when systemic vasoconstrictors (angiotensin II, catecholamines) are elevated — without prostaglandin counter-regulation, the afferent arteriole would constrict and renal perfusion would collapse
• Aspirin and other COX inhibitors abolish this protective vasodilation, leaving the kidney exposed to unopposed vasoconstriction

2. Sodium and Water Handling

• Medullary prostaglandins inhibit sodium reabsorption in the thick ascending limb of the loop of Henle
• They antagonize the antidiuretic action of vasopressin in the collecting duct
• Nonsteroidal anti-inflammatory drug-induced prostaglandin loss therefore promotes sodium and water retention — a common mechanism of nonsteroidal anti-inflammatory drug-related edema, weight gain, and worsening of heart failure or hypertension

3. Renin Release

• Cyclooxygenase-2-derived prostaglandins at the macula densa stimulate renin secretion from the juxtaglomerular apparatus
• Chronic nonsteroidal anti-inflammatory drug use can blunt renin release, occasionally causing hyporeninemic hypoaldosteronism with hyperkalemia — a recognized cause of nonsteroidal anti-inflammatory drug-induced potassium retention

4. Patient Populations Most Dependent on Renal Prostaglandins

• Adults over age 65 (declining nephron mass and baseline glomerular filtration rate)
• Heart failure (reduced effective arterial volume, high circulating angiotensin II)
• Cirrhosis with ascites (hepatorenal physiology, splanchnic vasodilation)
• Pre-existing chronic kidney disease of any cause
• Volume depletion: vomiting, diarrhea, diuretic therapy, hot-weather dehydration, surgical NPO status
• Sepsis or hypotension
• Concurrent use of angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin receptor blockers (ARBs), or calcineurin inhibitors

Acute Kidney Injury (AKI) from Aspirin and Nonsteroidal Anti-Inflammatory Drugs

Drug-induced acute kidney injury accounts for roughly 20% of all hospital-acquired acute kidney injury cases, and nonsteroidal anti-inflammatory drugs (NSAIDs) — including aspirin at higher analgesic and anti-inflammatory doses — are consistently among the most frequently implicated agents. Several distinct patterns of nonsteroidal anti-inflammatory drug-related kidney injury are recognized:

Hemodynamic (Pre-Renal) Acute Kidney Injury

• The most common nonsteroidal anti-inflammatory drug-induced renal syndrome
• Mechanism: loss of prostaglandin-mediated afferent arteriole vasodilation, reduced glomerular perfusion, fall in glomerular filtration rate
• Onset: hours to days after exposure, especially in volume-depleted or hemodynamically vulnerable patients
• Typically reversible if the drug is stopped early and volume is restored
• Bland urinalysis (no significant proteinuria, hematuria, or casts) is characteristic

Acute Interstitial Nephritis (AIN)

• An immune-mediated hypersensitivity reaction to the drug
• Onset typically weeks to months after starting the nonsteroidal anti-inflammatory drug, but can occur with any agent
• Often presents with sterile pyuria, white-cell casts, eosinophiluria (variable), and sometimes the classic triad of fever, rash, and eosinophilia (less common with nonsteroidal anti-inflammatory drugs than with antibiotics)
• Nonsteroidal anti-inflammatory drug-induced AIN is uniquely associated with concurrent nephrotic-range proteinuria caused by minimal change disease — an unusual two-hit pattern

Acute Tubular Necrosis

• Severe or prolonged ischemia from sustained renal hypoperfusion can progress from reversible pre-renal physiology to overt tubular cell injury
• This is the mechanism by which nonsteroidal anti-inflammatory drug exposure during sepsis, surgery, or contrast administration can produce a lasting drop in glomerular filtration rate

Reported Incidence

• Population-based cohort studies estimate that nonsteroidal anti-inflammatory drug use roughly doubles the short-term risk of acute kidney injury hospitalization in older adults compared with non-users
• The absolute risk in healthy adults is small, but in patients over 65 with pre-existing chronic kidney disease or heart failure the relative risk can rise three- to five-fold
• Risk is dose-dependent and rises sharply with higher anti-inflammatory dosing (≥ 1,200 mg/day of aspirin or equivalent nonsteroidal anti-inflammatory drug load)

Analgesic Nephropathy & Papillary Necrosis

Analgesic nephropathy is a slowly progressive form of chronic kidney disease caused by the long-term, heavy use of combination analgesic preparations — classically those containing phenacetin, paracetamol (acetaminophen), aspirin, and caffeine in the same tablet. It was first described in Switzerland in the 1950s and became a major cause of end-stage renal disease in parts of Europe and Australia before phenacetin was withdrawn from the market in the 1970s and 1980s.

Pathology

• Renal papillary necrosis: ischemic and oxidative damage to the renal medullary papillae, which can slough into the urinary tract and cause obstruction or hematuria
• Chronic interstitial nephritis: tubulointerstitial inflammation, fibrosis, and tubular atrophy
• Bilateral, symmetric atrophy: shrunken kidneys with characteristic papillary calcifications visible on computed tomography (CT) (the "garland sign")

Aspirin's Specific Role

• Phenacetin and its metabolite acetaminophen are now considered the principal nephrotoxic components of the historical combination analgesics
• Aspirin alone has weaker evidence as a sole cause of analgesic nephropathy, but it appears to potentiate phenacetin/acetaminophen toxicity by depleting glutathione and impairing medullary prostaglandin synthesis — the medulla relies on prostaglandins for its already marginal blood supply
• Heavy chronic users (often defined as a cumulative intake exceeding 2–3 kg over a lifetime, or daily use for many years) remain the population at risk
• Modern analgesic preparations no longer contain phenacetin, and the incidence of classical analgesic nephropathy has fallen sharply, but acetaminophen-NSAID combinations and chronic high-dose nonsteroidal anti-inflammatory drug use can still produce a similar clinical picture

Risk of Urothelial Cancer

• Long-term phenacetin use is also associated with transitional cell carcinoma of the renal pelvis and ureter
• Whether aspirin alone shares this risk is uncertain; large cohort studies have not consistently shown an excess urothelial cancer risk from aspirin without phenacetin

The "Triple Whammy": Nonsteroidal Anti-Inflammatory Drug + Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker + Diuretic

The combination of a nonsteroidal anti-inflammatory drug with both a renin-angiotensin system blocker (angiotensin-converting enzyme inhibitor (ACE inhibitor) or angiotensin receptor blocker (ARB)) and a diuretic is so consistently associated with acute kidney injury that it has been given a name in the nephrology and pharmacovigilance literature: the triple whammy. Each agent independently reduces a different compensatory mechanism the kidney relies on; together, they leave the glomerulus with no defense.

Why Each Component Matters

• Diuretic: contracts intravascular volume, raises circulating angiotensin II, and shifts the patient toward a prostaglandin-dependent state for maintenance of glomerular filtration rate
• Angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker: blocks angiotensin II's vasoconstriction of the efferent arteriole, lowering glomerular hydrostatic pressure
• Nonsteroidal anti-inflammatory drug (or aspirin at anti-inflammatory dose): blocks prostaglandin-mediated afferent arteriole vasodilation, lowering glomerular blood flow
• Net effect: simultaneous loss of preglomerular dilation and postglomerular constriction in a volume-contracted patient — glomerular filtration pressure collapses

Documented Risk

• A landmark BMJ cohort study (Lapi et al., 2013) found that triple therapy was associated with roughly a 31% increased rate of acute kidney injury compared with double therapy (RAS blocker + diuretic) without a nonsteroidal anti-inflammatory drug, with the highest risk in the first 30 days of triple therapy
• Subsequent population-based analyses have consistently confirmed the elevated acute kidney injury risk, especially in elderly patients
• The combination is considered a major preventable cause of community-acquired acute kidney injury

Clinical Implications

• Patients on chronic angiotensin-converting enzyme inhibitor/angiotensin receptor blocker plus diuretic therapy — including the very common heart failure and hypertension regimens — should avoid or minimize nonsteroidal anti-inflammatory drug use
• Cardioprotective low-dose aspirin (81 mg) carries far less hemodynamic risk than full-dose nonsteroidal anti-inflammatory drugs but is not entirely benign in this population, particularly during dehydrating illness
• Sick-day rules for older patients on RAS blockers and diuretics commonly recommend temporarily holding all three agents during vomiting, diarrhea, or febrile illness

Aspirin in Chronic Kidney Disease (CKD)

Patients with established chronic kidney disease face a difficult balance: they are at high cardiovascular risk and could benefit from antiplatelet therapy, but they are also more vulnerable to drug-induced kidney injury and bleeding. The evidence base for aspirin in chronic kidney disease is therefore nuanced.

Cardiovascular Risk in Chronic Kidney Disease

• Chronic kidney disease multiplies cardiovascular risk: a patient with estimated glomerular filtration rate (eGFR) 30–60 mL/min/1.73 m² has roughly twice the cardiovascular event rate of a person with normal kidney function, and risk rises further with worsening estimated glomerular filtration rate
• Cardiovascular disease, not progression to dialysis, is the leading cause of death in chronic kidney disease
• This makes secondary prevention with aspirin highly attractive in principle

Bleeding Risk in Chronic Kidney Disease

• Chronic kidney disease causes a uremic platelet dysfunction even before dialysis is needed, increasing baseline bleeding risk
• Adding aspirin compounds this and produces a documented increase in major bleeding, particularly gastrointestinal
• The KDIGO controversies conferences and major guideline bodies have stopped short of recommending routine primary-prevention aspirin in chronic kidney disease because the bleeding cost may equal or exceed the cardiovascular benefit

Renal Risk of Aspirin in Chronic Kidney Disease

• Low-dose aspirin (75–100 mg) has not been clearly shown to accelerate chronic kidney disease progression in well-conducted long-term studies
• Higher-dose aspirin and other nonsteroidal anti-inflammatory drugs have been linked to faster estimated glomerular filtration rate decline in observational cohorts
• For patients with established cardiovascular disease and chronic kidney disease, secondary-prevention aspirin is generally still considered net beneficial; for primary prevention in chronic kidney disease without prior events, the calculus is much closer and individualized

Low-Dose Aspirin (81 mg) — Does It Carry Less Renal Risk?

The 81 mg "baby aspirin" tablet provides enough irreversible platelet cyclooxygenase-1 inhibition to deliver the antithrombotic effect, while exerting only modest systemic COX inhibition. The renal risk profile is correspondingly different from that of full-dose aspirin or other nonsteroidal anti-inflammatory drugs.

Evidence Summary

• Large randomized trials of low-dose aspirin for cardiovascular prevention (including the Physicians' Health Study, the Women's Health Study, ASPREE, and ASCEND) have not shown a meaningful excess of clinically significant renal events compared with placebo
• Some observational data suggest a small absolute increase in acute kidney injury episodes among elderly low-dose aspirin users, particularly those who are also on diuretics or RAS blockers
• Long-term studies of analgesic exposure consistently identify higher cumulative aspirin doses (typically > 500 mg/day for years) as the threshold above which chronic kidney disease risk rises measurably
• Low-dose aspirin still carries the "triple whammy" risk if combined with a diuretic and an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker during volume depletion

Bottom Line on 81 mg

• For most adults with normal kidney function and adequate hydration, 81 mg daily poses minimal direct renal risk
• The renal risk becomes meaningful when combined with other COX inhibitors (such as ibuprofen for pain), with RAS blockade, with diuretics, or with significant volume depletion
• The dominant adverse effect of low-dose aspirin remains gastrointestinal bleeding, not nephrotoxicity

Aspirin in Dialysis Patients

Patients on chronic hemodialysis or peritoneal dialysis represent a distinct population in which the trade-off between cardiovascular protection and bleeding is sharpest.

Cardiovascular Burden

• Cardiovascular mortality in dialysis patients is roughly 10–20 times higher than in the age-matched general population
• Sudden cardiac death, myocardial infarction, and stroke are the leading causes of death

Bleeding Burden

• Uremic platelet dysfunction is severe in dialysis-dependent patients
• Heparin exposure during hemodialysis sessions adds further bleeding risk
• Dialysis patients have notably higher rates of gastrointestinal (GI) bleeding and intracranial hemorrhage than the general population

What the Evidence Shows

• Dialysis patients have been systematically excluded from most major aspirin cardiovascular outcome trials, so high-quality randomized data are sparse
• Observational studies and meta-analyses suggest that aspirin in dialysis patients does reduce major cardiovascular events but at the cost of an increase in major bleeding, with overall mortality benefit uncertain
• For dialysis patients with established coronary disease, aspirin is generally continued; for primary prevention, the decision is individualized and many nephrologists do not recommend it
• Aspirin does not directly worsen residual kidney function in anuric or near-anuric dialysis patients, since the hemodynamic mechanism that drives nonsteroidal anti-inflammatory drug-induced acute kidney injury is no longer relevant once the kidneys have failed; the concern shifts entirely to bleeding

Pediatric Considerations & Reye's Syndrome

Aspirin is contraindicated in children and adolescents recovering from viral illnesses because of its association with Reye's syndrome — a rare but devastating disorder of acute hepatic failure and non-inflammatory encephalopathy. Although Reye's syndrome is fundamentally hepatic-cerebral rather than renal, it has metabolic features relevant to the broader question of aspirin pharmacology in children.

Pathophysiology

• Reye's syndrome involves diffuse mitochondrial injury, particularly in hepatocytes and neurons, with microvesicular hepatic steatosis, hyperammonemia, and cerebral edema
• Affected children typically have a preceding viral illness (classically influenza or varicella) and a history of aspirin or salicylate exposure
• The mitochondrial injury appears to involve impaired beta-oxidation of fatty acids and inhibition of oxidative phosphorylation
• Cytochrome P450 (CYP) enzymes contribute to salicylate metabolism, and immature pediatric CYP activity may produce reactive intermediates that worsen mitochondrial stress during viral illness

Renal Involvement

• Reye's syndrome itself can include renal tubular dysfunction with proximal tubular wasting of amino acids and phosphate
• Hypovolemia and hepatic failure can produce hepatorenal physiology and secondary acute kidney injury
• These renal manifestations are secondary to the systemic illness rather than direct aspirin nephrotoxicity

Practical Rule

• Aspirin should not be used in children or teenagers under 19 with viral illnesses, fever of unknown cause, or chickenpox
• Acetaminophen and ibuprofen are the standard pediatric antipyretics — though both also carry their own renal cautions, particularly in dehydrated febrile children
• The rare exceptions in which children are prescribed aspirin (Kawasaki disease, certain rheumatic and post-cardiac-surgery indications) are managed by pediatric specialists

Practical Guidance: Avoidance, Monitoring, Hydration

Patients Who Should Generally Avoid Aspirin (or Use With Specialist Input)

• Adults with estimated glomerular filtration rate < 30 mL/min/1.73 m², except where cardiovascular indications outweigh bleeding risk
• Patients with active or recent gastrointestinal bleeding
• Patients with decompensated heart failure or cirrhosis with ascites
• Anyone with a history of nonsteroidal anti-inflammatory drug-induced acute kidney injury, interstitial nephritis, or papillary necrosis
• Children and adolescents with viral illness (Reye's syndrome risk)
• Pregnant patients in the third trimester (nonsteroidal anti-inflammatory drug and aspirin use can constrict the fetal ductus arteriosus and impair fetal renal function with oligohydramnios; low-dose aspirin used for preeclampsia prevention is given earlier in pregnancy under obstetric supervision)

Sick-Day Rules

• During acute vomiting, diarrhea, or febrile illness, temporarily hold any nonsteroidal anti-inflammatory drug, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, diuretic, sodium-glucose cotransporter-2 (SGLT2) inhibitor, and metformin until oral intake is restored
• Low-dose cardioprotective aspirin is sometimes continued at the prescriber's discretion, but the threshold for holding it lowers if dehydration is significant
• Resume medications once eating, drinking, and urine output have returned to normal

Monitoring

• For patients on chronic aspirin who develop new acute kidney injury risk factors, baseline serum creatinine and a follow-up measurement within 1–2 weeks of any change in regimen are reasonable
• In hospitalized patients receiving aspirin alongside other nephrotoxins or contrast, daily creatinine monitoring is standard
• Older patients on chronic nonsteroidal anti-inflammatory drugs of any kind should have annual estimated glomerular filtration rate and urine albumin assessments

Hydration and Concurrent Medications

• Adequate hydration is the single most important modifiable factor for reducing aspirin- and nonsteroidal anti-inflammatory drug-related acute kidney injury
• Avoid stacking nonsteroidal anti-inflammatory drugs — do not combine cardioprotective aspirin with daily ibuprofen, naproxen, diclofenac, or topical diclofenac in large amounts
• If pain control is needed in a patient who must remain on aspirin, acetaminophen at appropriate doses is generally preferred from a renal-safety standpoint, with awareness of its hepatic considerations
• Coffee consumption has been associated with a modestly lower incidence of acute kidney injury in observational studies (Johns Hopkins ARIC analysis), and adequate caffeine-free fluid intake supports renal perfusion — but neither is a substitute for sound prescribing

Key Research Papers

Renal Prostaglandins & Nonsteroidal Anti-Inflammatory Drug Mechanism

1. Search PubMed
2. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine. 1984;310(9):563-572. — doi:10.1056/nejm198403013100905
3. Nasrallah R, Hassouneh R, Hébert RL. Chronic kidney disease: targeting prostaglandin E₂ receptors. American Journal of Physiology — Renal Physiology. 2014;307(3):F243-F250. — doi:10.1152/ajprenal.00224.2014

Nonsteroidal Anti-Inflammatory Drug-Induced Acute Kidney Injury & Triple Whammy

4. Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 2013;346:e8525. — doi:10.1136/bmj.e8525
5. Search PubMed
6. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case-control analysis. American Journal of Epidemiology. 2006;164(9):881-889. — doi:10.1093/aje/kwj331
7. Nderitu P, Doos L, Jones PW, Davies SJ, Kadam UT. Non-steroidal anti-inflammatory drugs and chronic kidney disease progression: a systematic review. Family Practice. 2013;30(3):247-255. — doi:10.1093/fampra/cms086

Analgesic Nephropathy & Papillary Necrosis

8. De Broe ME, Elseviers MM. Analgesic nephropathy. New England Journal of Medicine. 1998;338(7):446-452. — doi:10.1056/nejm199802123380707
9. Search PubMed
10. Mihatsch MJ, Khanlari B, Brunner FP. Obituary to analgesic nephropathy — an autopsy study. Nephrology Dialysis Transplantation. 2006;21(11):3139-3145. — doi:10.1093/ndt/gfl390

Aspirin in Chronic Kidney Disease & Cardiovascular Prevention

11. McNeil JJ, Wolfe R, Woods RL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly (ASPREE). New England Journal of Medicine. 2018;379(16):1509-1518. — doi:10.1056/NEJMoa1805819
12. ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. New England Journal of Medicine. 2018;379(16):1529-1539. — doi:10.1056/NEJMoa1804988
13. Palmer SC, Di Micco L, Razavian M, et al. Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis. Annals of Internal Medicine. 2012;156(6):445-459. — doi:10.7326/0003-4819-156-6-201203200-00007
14. Jardine MJ, Ninomiya T, Perkovic V, et al. Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology. 2010;56(12):956-965. — doi:10.1016/j.jacc.2010.02.068

Low-Dose Aspirin Renal Safety

15. Search PubMed
16. Search PubMed

Reye's Syndrome & Pediatric Aspirin

17. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications. Report of the pilot phase. New England Journal of Medicine. 1985;313(14):849-857. — doi:10.1056/nejm198510033131403
18. Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye's syndrome in the United States from 1981 through 1997. New England Journal of Medicine. 1999;340(18):1377-1382. — doi:10.1056/nejm199905063401801

Back to Table of Contents

Connections

• All Remedies
• Aspirin Overview
• Celery Juice and Kidney Disease
• Aspirin for Heart Attack Prevention
• Aspirin Health Benefits
• Aspirin Side Effects
• N-Acetylcysteine
• Mercury
• Kidney Disease
• Acute Kidney Injury
• Estimated Glomerular Filtration Rate
• Kidney Function Tests
• Heart Failure
• Hypertension
• Aspirin and Cancer Prevention
• Aspirin for Stroke Prevention
• Creatinine
• Coffee
• Kidney Injury

×

Featured Videos